Should I buy Neurocrine Biosciences (NBIX) stock or is it too late?

Neurocrine Biosciences · Health Care · price $156

See the full Neurocrine Biosciences (NBIX) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 77% of its targets hit on this sector (52 calls tested). It aims for $222 (+42 %), call made on August 1, 2026, maturing on August 1, 2027 (27 d ago).

The 10 reliable analysts $214+37 %

The 8 other firms $195+25 %

How to read it: the 10 reliable firms are not filtered by optimism — 10 aim above the price, 0 below, hence their $214 median. “The 8 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Neurocrine Biosciences

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Piper Sandler	100 %	+33.6 %	7	$210 +35%
RBC Capital	100 %	+28.5 %	6	$198 +27%
Citigroup	67 %	+23.8 %	6	$249 +60%
Oppenheimer	57 %	+20.1 %	14	$219 +40%
UBS	67 %	+18.7 %	9	$178 +14%
Guggenheim	67 %	+13.4 %	6	$222 +42%
Canaccord Genuity	60 %	+10.7 %	15	$210 +35%
Stifel	60 %	+9.0 %	5	$215 +38%

In short — Should you invest in Neurocrine Biosciences? Is it too late, still worth it? Analysts are overwhelmingly positive (89% buy, median target $210, i.e. +35%), and the most reliable on NBIX targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

89% of analysts rate it a buy (Buy consensus, 18 ratings) — a sign of market conviction.
Median price target $210, i.e. +35% from the current price ($156).
The most reliable firm on NBIX, Piper Sandler (100% hit rate, 7 scored calls), targets $210 (call made on July 31, 2026, maturing on July 31, 2027) (+35%) in its most recent call, and $207 (call made on May 6, 2026, maturing on May 6, 2027) (+33%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 18 ratings, 2 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on NBIX

Median target $210 (+35%) · 18 ratings · Buy consensus

Strong Buy00%

Buy1689%

Hold211%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Neurocrine Biosciences now?

We won't decide for you. The facts: 89% of analysts rate it a buy, median target $210 (+35%), and Piper Sandler (most reliable on NBIX, 100%) targets $210. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Neurocrine Biosciences?

Not according to analysts: the median target ($210) is still +35% above the current price ($156) (most reliable on NBIX: Piper Sandler, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Neurocrine Biosciences still worth investing in?

It depends on the gap between the price ($156) and its estimated value: analysts target $210 on median (+35%), with 89% buys (most reliable on NBIX: Piper Sandler, 100%). Cross-check with their real reliability on NBIX and the cautions above. Information, not advice.

What's the main risk in buying NBIX?

The consensus is not unanimous: of 18 ratings, 2 are neutral.

→ Go deeper: the full Neurocrine Biosciences profile (consensus, analyst reliability, price target, performance).